monoclonal antibody
FDA Approves Veopoz for CHAPLE Disease
The FDA approved Veopoz as the first treatment for CD55-deficient protein-losing enteropathy, also known as CHAPLE ...
AUGUST 21, 2023
3-Drug Regimen With 2 Biologics Deployed in High-Risk Crohn’s Trial
The combination of two monoclonal antibodies targeting different inflammatory mediators plus methotrexate was found ...
SEPTEMBER 14, 2022
FDA Limits Use of Monoclonal Antibodies to Treat COVID-19
The FDA revised the EUAs for two monoclonal antibody cocktails for COVID-19, essentially saying the should not be ...
JANUARY 25, 2022
Regen-COV Reduces Viral Load in Patients Hospitalized with COVID-19
The monoclonal antibody cocktail may be as useful in the hospital as it is in the outpatient setting.
OCTOBER 6, 2021
Low Uptake of FDA-Authorized mAb Treatments for COVID-19
Eighteen months into the pandemic, monoclonal antibodies (mAbs) remain the only FDA-authorized outpatient treatment ...
SEPTEMBER 17, 2021
JAK Inhibitors, IL-6 Blockers for COVID-19: Where Do They Fit?
Another JAK inhibitor appears effective in reducing death and respiratory failure in patients hospitalized with ...
JULY 6, 2021
FDA Authorizes Lower Dose of Regen-Cov mAb Cocktail
The FDA updated the emergency use authorization (EUA) for Regeneron’s Regen-Cov, lowering the dose to 1,200 ...
JUNE 4, 2021
Tanezumab Shown to Reduce Low Back Pain In Comparison Study
Tanezumab, an investigational monoclonal antibody that inhibits nerve growth factor, was similar to tramadol in ...
JANUARY 15, 2021
FDA Authorizes mAb Cocktail for Treatment of COVID-19
Casirivimab and imdevimab should be administered together for the treatment of mild to moderate COVID-19 patients ...
NOVEMBER 24, 2020
FDA Approves Takhzyro for Rare Hereditary Angioedema
Takhzyro is the first monoclonal antibody approved in the United States to prevent attacks of hereditary angioedema ...
AUGUST 27, 2018
Aimovig Gets FDA Nod for Migraine Prevention
Aimovig is the first FDA-approved treatment to block the calcitonin gene–related peptide receptor, which ...
MAY 18, 2018
Pfizer Announces Positive Results From the Comparative Study for Potential Biosimilar to Humira
The primary end point was an equivalent ACR20 response at week 12 of study treatment.
JANUARY 6, 2017
